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Purpose. The purpose of this study was to determine the feasibility and preliminary eﬃcacy of a cardiac rehabilitation (CR)
intervention in the breast cancer population. Methods. This single-arm feasibility study evaluated a 14-week CR intervention
program in breast cancer survivors. Feasibility was deﬁned as completion of at least 30/36 sessions of the program without serious
adverse events (SAE) in 80% of patients. Secondary endpoints included the change in VO2 max, cardiovascular disease (CVD) risk
factors, Duke Activity Secondary Index (DASI), Brief Fatigue Inventory (BFI), and QLQ-C30. All outcomes were reported as
mean change and compared using paired t-tests. Results. A total of 25 patients were enrolled in the study. 18 patients of the 25
enrolled (72%) completed the 14 weeks program without SAE. The overall adherence to the study protocol was 60%. Of the 18
participants who did not withdraw from the program, 15 (83%) adhered to the study protocol and completed 30 or more sessions.
There was a nonsigniﬁcant improvement in VO2 max (mean Δ0.5, p � 0.6). The scores for DASI, BFI, and QLQ-C30 improved
from baseline to posttreatment. Conclusion. A CR intervention in breast cancer survivors had high adherence in those who were
able to complete the 14-week program. The program signiﬁcantly improved patient reported physical activity, fatigue, and quality
of life (QoL), without signiﬁcant improvement in CVD risk factors. Implications for cancer patients are that early implementation
of a CR program should be considered by practitioners as it improves QoL and exercise tolerance in breast cancer survivors.

1. Introduction
Cardiovascular disease (CVD) is the leading cause of death
among women in the general population and among breast
cancer survivors speciﬁcally [1, 2]. Increased utilization of
mammographic screening and adjuvant therapy has improved the long-term survival of women with breast cancer.
There are now more than 2.5 million female breast cancer
survivors in the United States [1]. As more women survive

longer, their risk of death from other causes has increased
such that the majority of breast cancer survivors ultimately
die of CVD rather than from cancer [3, 4]. Important risk
factors such as physical inactivity, advanced age, obesity, and
smoking are common to the etiology of both CVD and
breast cancer [1–3]. A recent evaluation of National Health
and Nutrition Examination Survey data highlighted the
possible role of shared risk factors in the development of
cancer, reporting that over 90% of cancer survivors have
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multiple CVD risk factors [4]. Achieving favorable changes
in risk factors common to both CVD and cancer are associated with improved CVD and cancer survival, as well as
lower cancer recurrence [5, 6]. Better strategies for managing
and preventing CVD are needed for this population.
Evidence suggests that exercise also decreases long-term
side eﬀects from cancer treatments among breast cancer
survivors and may provide additional physiological and
psychological beneﬁts [7, 8]. A program of regular exercise
may also reduce levels of CVD risk factors and the resulting
risk of future cardiovascular events [9, 10]. Existing studies
only touched the surface of the feasibility of outpatient
cardiac rehabilitation (CR) programs for the reduction of
CVD risk among breast cancer survivors, especially those
susceptible to the late eﬀects of chest radiation and cardiotoxic cancer treatments such as trastuzumab, doxorubicin, and aromatase inhibitor therapy [3, 11].
A CR program is a unique model for providing an exercise intervention to breast cancer survivors. As per the
statement from the American Heart Association for the need
for eﬀective and viable strategies to mitigate cardiovascular
disease risk in cancer population, cardiac rehabilitation can
play a role for potential solution. AHA statement provides
an overview of the existing knowledge and rationale for the
use of cardiac rehabilitation to provide structured exercise
and ancillary services to cancer patients and survivors [12].
The CR program is deﬁned as “the provision of comprehensive long-term services involving medical evaluation,
prescriptive exercise, cardiac risk factor modiﬁcation, and
education, counseling, and behavioral interventions” [13].
CR is characterized by its evidence-based protocol and attention to exercise principles, including frequency, intensity,
and duration [14], which is lacking in existing exercise
studies [7, 15, 16]. CR programs are tailored exercise programs, which are modiﬁable according to the baseline
cardiorespiratory ﬁtness level and comorbid disease status of
the participants and are designed to induce changes in the
CVD risk proﬁle of participants [17, 18].
Although CVD and breast cancer share many important
risk factors, this current study is the ﬁrst to study the
implementation and feasibility of CR among breast cancer
survivors posttreatment to improve cardiorespiratory ﬁtness, reduce CVD risk, and improve quality of life (QoL).
Earlier existing studies report increased CVD risk among
breast cancer survivors [4] but have not yet assessed the
feasibility of outpatient CR programs for the reduction of
CVD risk among breast cancer survivors, especially those
susceptible to the late eﬀects of chest radiation and medical
treatments. Treatments including drugs such as trastuzumab, doxorubicin, and most recently, aromatase inhibitor
therapy are associated with this increased risk of cardiotoxicity [1, 11].
The purpose of this study was to assess the feasibility of a
CR program in breast cancer survivors and to evaluate
cardiorespiratory ﬁtness, CVD risk factors, and patient reported outcome measures before and after the intervention.
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2. Methods
This was a single-arm prospective feasibility study of a 36session (14-week) CR intervention in female breast cancer
survivors. A sample size of 20 participants was initially planned
to evaluate the feasibility of the CR program. An additional ﬁve
participants were accrued to account for attrition.
Participants’ recruitment, eligibility screening, and consent occurred at the time of their appointment of their ﬁnal
breast cancer treatment and/or subsequent follow-up appointments. Women between the ages of 30 and 75 with
stages 0–III breast cancer who were within 18 months of
treatment including surgery, radiation, and/or chemotherapy,
regardless of type and duration were eligible for the study.
Patients could be receiving ongoing endocrine therapy or
trastuzumab. Individuals with existing CVD, contraindications to exercise, or cardiac stress testing, metastatic breast
cancer, other concurrent malignancies except skin cancer,
active infection, psychiatric illness/social situation that would
limit compliance with study requirements, or who were
pregnant or breastfeeding were excluded from the study. An
exercise prescription, approved per protocol by the CR
program director and cardiac rehabilitation staﬀ, was developed for each participant in the intervention group to
guide the CR sessions.
This study was approved by the Ohio State University
Medical Center Cancer Institutional Review Board and
followed IRB guidelines.

2.1. Procedures. Demographics, clinical data, and inclusion/
exclusion criteria were obtained and recorded for all patients. Variables of interest were participants’ age, self-reported race/ethnicity, cancer treatment details, and medical
history. Breast cancer patients typically progress through
treatment in the following order: surgery, chemotherapy,
and radiation therapy, though not all patients progress
through each step. We recruited patients from their treatment close-out appointment to participate in the study,
regardless of type or duration of therapy received. The rationale for the proposed research is that cardiac rehabilitation programs have substantial extant infrastructure and
may improve morbidity and mortality from both CVD and
cancer among breast cancer patients posttreatment.
The CR program consisted of one-hour sessions, three
times per week for a maximum of 14 weeks and for a
minimum total of 36 sessions. The program took place at an
outpatient CR center at the Ohio State University Medical
Center that was designated for cardiac patients. An exercise
prescription, approved per protocol by the CR program
director and cardiac rehabilitation staﬀ, was developed for
each participant to guide the CR sessions according to the
cardiorespiratory ﬁtness level of the participant. During each
session, participants started the intervention at a workload of
60–85% of their VO2 max as determined in advance by a
graded exercise stress test using the Bruce protocol [19]. The
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goal was to increase the duration of this workload to 45
minutes throughout the intervention period. Participants
were encouraged to supplement their exercise program at
home and to increase the frequency of exercise to ﬁve times
per week.
A cardiac stress test was performed at baseline and week
14. The participants were instructed on the use of the Borg
Perceived Exertion Scale for reporting their subjective level
of exertion during the test [20]. The stress testing technician
monitored the participants for symptoms such as chest pain
or shortness of breath and ensured that the vital signs
returned to normal following the test.
Patient questionnaires were administered at baseline,
week 8, and week 14. Systolic and diastolic blood pressure
(BP), a fasting lipid panel, fasting glucose, height and weight,
and body mass index (BMI) of participants were checked at
baseline and at the end of the 14-week intervention period.
During the 14-week intervention period, the CR staﬀ
contacted participants by phone to remind them of their
upcoming CR appointments for the week. The participants
received a $20 per week stipend for the 14-week intervention
period to help oﬀset travel costs to and from the CR facility.
Upon completion of the 14-week assessment, all participants
received an additional $50 stipend.
2.2. Measures
2.2.1. Cardiorespiratory Fitness. Cardiorespiratory ﬁtness
was measured by the participants VO2 max in mL/kg/min at
baseline and at the end of the 14-week intervention period.
The VO2 max was directly obtained from all study participants using a face mask that measured the concentration of
inhaled and exhaled gasses during a graded exercise stress
test using the Bruce protocol [19]. During the test, the intensity of exercise was gradually increased. The participants’
VO2 max was reached when the value of VO2 did not
change with an associated increase in exercise intensity. If
participant requested the graded exercise test to be stopped
prior to reaching their VO2 max, their submaximal VO2 was
recorded as their VO2 max. This test was performed on a
treadmill. The graded exercise stress test protocol and related
CR patient education classes including nutrition, weight
training principles, medications, and heart disease followed
the standard CR program. The participants’ BP, heart rate,
rate of perceived exertion (RPE) [20], and any symptoms
including chest pain or shortness of breath were monitored
before, during, and after the exercise.
2.2.2. CVD Risk Factors. CVD risk factors including BP,
heart rate (HR), BMI, fasting total low-density lipoprotein
(LDL), total cholesterol, and fasting glucose were measured
at baseline and at the end of the 14-week intervention period.
The systolic and diastolic BP (mm/Hg) of each participant
was assessed three times at one-minute intervals after the
participant was seated with legs uncrossed for 5 minutes. The
last two readings were averaged for the BP measurement.
Height (cm) and weight (kg) were measured without shoes,
and BMI (kg/m2) was calculated from these measurements.
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2.3. Patient-Reported Outcomes
2.3.1. Physical Activity. The Duke Activity Status Index
(DASI) questionnaire was used to assess self-reported
physical activity among all participants. The DASI is a 12item questionnaire that assesses both activities of daily living
and leisure-time physical activity. The summed score correlates with peak oxygen consumption [21]. Higher scores
indicate higher functional capacity. The DASI has been
shown to be valid, reliable, and independently prognostic of
cardiac events in women [21].
2.3.2. Quality of Life (QoL). The European Organization for
Research and Treatment of Cancer QoL core questionnaire
(EORTC QLQ-C30) and its associated breast cancer module
(EORTC QLQ-BR23) were used to measure QoL and were
scored according to the EORTC scoring manual [22]. The
EORTC questionnaires are validated tools designed to assess
QoL among cancer patients across several dimensions, including global health status, social functioning, fatigue,
nausea and vomiting, pain, dyspnea, insomnia, loss of appetite, constipation, diarrhea, and ﬁnancial strain. The QLQBR23 expands the functional scales to include body image,
sexual functioning, sexual enjoyment, breast symptoms, arm
symptoms, and hair loss. The EORTC questionnaire was
self-administered with paper and pencil. If the participants
missed their 8-week visit or did not attend their 14-week
visit, the EORTC questionnaire was administered by phone
or mail.
2.3.3. Fatigue. The Brief Fatigue Inventory (BFI) questionnaire was used to measure self-reported fatigue. BFI is an
instrument for evaluation of fatigue and its impact on daily
life in patients with cancer. The BFI is a short, validated
measure of fatigue severity which complements ﬁndings
from the EORTC questionnaires [23].
2.3.4. Participant Satisfaction. Participants were asked to
rate their degree of satisfaction with the exercise portion of
the program, the education portion of the program, and the
overall cardiac rehabilitation experience on a scale of 1–10,
with 1 being extremely dissatisﬁed and 10 being extremely
satisﬁed.
2.3.5. Adverse Events. Adverse events were reported using
the Common Terminology Criteria for Adverse Events v4.0
(CTCAE) of the National Cancer Institute. Grade 3, grade 4,
and grade 5 toxicities were reported as adverse events.
2.4. Statistical Analysis. The primary endpoint of the study
was to assess the feasibility of conducting a 14-week CR
program in women with breast cancer after completion of
therapy. Feasibility was deﬁned as completion of at least 30
sessions of the program without serious adverse events
(SAE) in 80% of patients and was reported as a percent with
95% conﬁdence interval.
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Secondary endpoints of the study included the change in
cardiorespiratory ﬁtness and DASI. Tertiary endpoints included CVD risk factors, QoL, and patient satisfaction at
baseline and 14 weeks.
Summary statistics for patient demographics and disease
characteristics were calculated. The proportion of participants who completed the CR program was calculated, along
with the 95% conﬁdence interval (CI). The change in each
endpoint from baseline to 14 weeks was calculated and
summarized by mean, standard deviation, and 95% CI. The
diﬀerence in these outcomes from baseline to 14 weeks was
compared using either a two-sample t-test or sign-rank test.
All data analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC).

3. Results
3.1. Feasibility. Twenty-ﬁve participants were consented and
enrolled in the study (Figure 1). Participant characteristics
are summarized in Table 1 and cancer characteristics are
summarized in Table 2. The median age was 53 (range:
35–71), and the majority of women had ER/PR positive/
Her2-neu negative (n � 13, 54%), stage I (n � 13, 54%) or II
(n � 7, 30%) breast cancer.
Seventy-two percent (n � 18) of those participants who
enrolled completed the CR program (95% CI: 50.6, 87.9).
Seven participants withdrew from the study. One patient
could not tolerate the schedule, one did not want to start the
program, two developed an arrhythmia during the program
and were unable to return, two withdrew consent, and one
did not return for the program for undocumented reasons.
60% of those enrolled in the study (95% CI: 42.5, 82.0)
completed 30 or more sessions and adhered to the study
protocol. Of the 18 participants who did not withdraw from
the CR program, 83% (n � 15) adhered to the study protocol
and completed 30 or more sessions without SAEs.
3.2. Cardiorespiratory Fitness and CVD Risk Factors.
Secondary outcomes included the change in cardiorespiratory ﬁtness and CVD risk factors. There was a modest
improvement in the VO2 max from the start of CR program
to 14 weeks follow-up (mean Δ0.5, 95% CI: −20.0, 5.6,
p � 0.587) (Figure 2).
There was also some improvement in CVD risk factors
including HR (Δ0.95, 95% CI: −2.8, 4.7, p � 0.595), systolic
BP (Δ1.76, 95% CI: −5.5, 9.0, p � 0.612), and diastolic BP
(Δ5.18, 95% CI: −0.5, 10.9, p � 0.071) between baseline and
14-week follow-up. Improvements were also found in BMI
(Δ−0.14, 95% CI: −0.9, 0.7, p � 0.714), fasting blood glucose
(Δ−0.53, 95% CI −5.4, 4.34, p � 0.821), total cholesterol
(Δ−4.71, 95% CI: −23.1, 13.7, p � 0.589), and LDL cholesterol (Δ−4.93, 95% CI: −22.8, 12.9, p � 0.561. Although
these secondary and tertiary outcomes did show improvement, the study was not powered to detect statistical
signiﬁcance.
3.3. Patient-Reported Outcomes. There was improvement in
the patient reported physical activity according to the DASI
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(mean Δ13.2; p < 0.001), mean BFI score (mean Δ−1.7; 95%
CI: −2.9, −0.5, p � 0.007), and QLQ-C30 (Δ5.66; 95% CI:
1.68, 9.63, p � 0.008) scores during the treatment period.
Figure 3 shows the changes in BFI and QLQ-C30 score at
baseline, 8-week follow-up, and 14-week follow-up. Patients
reported improvement in their fatigue and quality of life on
the BFI (p � 0.007) and QLQ-C30 (p � 0.008) as early as at
the 8-week study period. On the BR23 scales, participants
reported improvement in body image, sexual functioning,
breast symptoms, and systemic therapy side eﬀects over the
14-week period.
3.4. Patient Satisfaction. Of those 18 participants who
remained in the CR program until the end of the 14 weeks,
15 participants (83.3%) rated they were very to extremely
satisﬁed, with the majority (n � 12, 67%) reporting extreme
satisfaction, with the exercise portion of the program. Most
of the participants (n � 11, 1%) were also very to extremely
satisﬁed with the education component of the program, and
15 participants (83.3%) were very to extremely satisﬁed with
the overall CR experience.
3.5. Adverse Events. Two patients withdrew from the study
due to serious adverse events related to cardiac arrhythmias.
One patient experienced ventricular tachycardia (grade 4)
and required cardiac catheterization during the study period
and could not continue with the study protocol past week 10.
Another patient experienced supraventricular tachycardia
(SVT), and the patient could not return to the study protocol
following treatment for the SVT (grade 3). These events did
not occur during the CR sessions, but are possibly related to
the study intervention. Moreover, one patient experienced a
headache during the study intervention (grade 1).

4. Discussion
The breast cancer survivors who successfully completed the
14-week CR intervention have shown signiﬁcant improvement in patient reported physical activity, fatigue, and
quality of life (QoL), but without signiﬁcant improvement in
CVD risk factors. Our long-term goal is to decrease the
burden of CVD among breast cancer survivors. Moreover,
with our central hypothesis, the cardiac rehabilitation intervention will improve cardiorespiratory ﬁtness, CVD risk
factors, and QoL among survivors. To mitigate CVD risk in
cancer patients, there is a need of eﬀective strategies, and the
use of a cardiac rehabilitation (CR) programs has been
signiﬁcantly helpful in selected patients. The cardiooncology
rehabilitation (CORE) model has been used to identify
patients at high risk of CVD including cardiotoxicity due to
cancer therapies [12]. Recent evidence indicated that a CR
program is clinically beneﬁcial and cost eﬀective; also, the
quality of delivery of a CR program is associated with the
morbidity proﬁle of patient population, and the role of
exercise, physical activity, and nonpharmacological treatments are proven as a preventive measure for cardiovascular
toxicity and modiﬁed cardiovascular risk in cancer survivors
[24–28].
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Patients with breast cancer
stages I–III who consented and
assessed for eligibility
(n = 25)

Patients who withdrew consent prior to
starting CR program
(n = 1)

Patients who attended at least 1 CR session
(n = 24)

Patients who withdrew consent during the CR
program before completing 14 weeks
(n = 5)

Patients on CR who had too many missing
variables
(n = 1)

Patients who completed 14 weeks
of CR on study
(n = 18)

Patients who completed ≥30 CR sessions on
study
(n = 15)

Patients who completed 14 weeks of CR
on study but attended <30 CR sessions
(n = 3)

Figure 1: Consort diagram.

Table 1: Summary of demographic and screening variables.
Variable
Age

Level

Total (n � 24)

Median (IQR)
(min, max)

53 (46, 60)
(35, 71)

Asian
Black or African American
White

1 (4%)
2 (8%)
21 (88%)

Non-Hispanic

24 (100%)

Race

Ethnicity

It is estimated that nearly 90% of women diagnosed with
breast cancer will be alive in 5 years, which has important
implications for CVD morbidity and mortality [29]. Unfortunately, the eﬀects of breast cancer treatment are known
to cause cardiotoxicity [30]. For example, anthracycline
therapy, which is often a component of neoadjuvant and
adjuvant therapy for high-risk breast cancer, can cause dosedependent cardiotoxicity that leads to left ventricular dysfunction, congestive heart failure [31]. Trastuzumab can
increase the risk of heart failure and left ventricular ejection
fraction decline [32]. Radiation therapy to the breast or chest
wall has been associated with dose-dependent cardiotoxicity
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Table 2: Summary of screening tumor characteristic variables.

Variable
Breast cancer staging (overall)

Level

Total (n � 24)

IA
IB
IIA
IIB
IIIA
IIIB

12 (50%)
1 (4%)
4 (17%)
3 (13%)
2 (8%)
2 (8%)

0
1
2
6
8

18 (75%)
2 (12%)
2 (8%)
1 (4%)
1 (4%)

Missing
No
Yes

1 (4%)
22 (92%)
1 (4%)

Negative
Positive

4 (17%)
20 (83%)

Negative
Positive

6 (25%)
18 (75%)

0
1
2
3

9 (38%)
8 (33%)
2 (8%)
5 (21%)

Negative
Positive

17 (71%)
7 (29%)

Missing
ER+/PR+/
HER2+
ER+/PR+/
HER2−
ER+/PR−/
HER2+
ER+/PR−/
HER2−
ER−/PR−/
HER2+
ER−/PR−/
HER2−

1 (4%)

# of nodes

History of prior cardiac events, previous diagnosis of hypertension, hypercholesterolemia, or diabetes?

Estrogen receptor
Progesterone receptor

Her2-neu (IHC)

Her2-neu (FISH)
ER/PR/Her2-neu
4 (17%)
13 (54%)
1 (4%)
1 (4%)
2 (8%)
2 (8%)

Grade
1
2
3

3 (12%)
10 (42%)
11 (50%)

Bilateral
Left
Right

1 (4%)
12 (50%)
11 (46%)

Median
(min, max)

1.5
(0.4, 3.8)

Location of primary breast tumor

Tumor size

which leads to radiation-induced ﬁbrosis of the myocardium
and microvascular damage to the coronary vasculature that
accelerates atherosclerosis and development of coronary

artery disease [33]. As immunotherapy becomes part of the
standard of care for breast cancer treatment, the cardiotoxic
eﬀects of monoclonal antibody-based or targeted kinase
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100
90
80
70
60
50
40
30
20
10
0

Baseline

Cycle 14

Figure 2: Change in VO2 max from baseline to cycle 14. Each individual color represents a diﬀerent participant and their change in VO2
max from baseline to end of study at cycle 14.

100

QLQ-C30 summary score

BFI

6

4

2

90

80

70

0
0

8
Weeks

14

(a)

0

8
Weeks

14

(b)

Figure 3: Box-plot showing the summary statistics for BFI and QLQ-C30 summary score by cycle. Mean (diamond), median (white line),
and the 1st and 3rd quartiles (Q1: bottom and Q3: top of box) are displayed. The whiskers are the distance equal to 1.5 times the interquartile
range (IQR) from Q1 and Q3. The diagram also shows outliers (circles) which are values that are above or below the whisker ends (Q1 − 1.5∗
IQR and Q3 + 1.5∗ IQR).

therapies may contribute to the problem [34]. The shared
risk factors combined with cardiotoxicity from breast cancer
treatments increase the susceptibility of developing CVD,
known as the “multiple-hit” hypothesis [35].
A recent report indicates that older female breast cancer
survivors were more likely to die of CVD than breast cancer.
Moreover, those patients that had comorbid conditions,
such as CVD, had similar or worse survival compared to
survivors with a higher stage of breast cancer without these
comorbid conditions [36]. Early recognition of patients who
are at risk of cardiac toxicity from their treatment and other
risk factors for cardiac disease is essential in improving
outcomes for breast cancer survivors [37].
The primary objective of this study was to assess the
feasibility of a CR program in the breast cancer population
and is one of the ﬁrst studies to prospectively assess the
feasibility of a CR regimen in this population. Although only
60% of those enrolled on the study adhered to the protocol,
83% of those who completed the CR program were able to
adhere to the program and complete 30 or more sessions.
This rate is similar to an average completion rate of 60% for

the general CR population [38]. The ﬁndings are also
consistent with completion rates in other studies of cardiac
rehabilitation in cancer survivors and are much higher than
that reported in a prospective study of breast cancer survivors using a community CR program who had an adherence rate of 30% [39]. Consistent with a previous
retrospective study of CR in breast cancer patients that
found an increase in VO2 max in participants [40], we found
a nonsigniﬁcant increase in VO2 max in participants from
baseline to the end of the program. As Table 3 demonstrates,
other non-CR based exercise interventions have also demonstrated a beneﬁt of exercise on VO2 max for women with
breast cancer by attenuating the eﬀects of chemotherapy
during breast cancer treatment and by allowing recovery of
cardiopulmonary function after the completion of treatment
for breast cancer [46]. The study also found that participant’
self-reported physical activity increased based on the DASI
during the program, which is consistent with other studies
that have shown an increase in cardiopulmonary ﬁtness and
overall physical function after an exercise program based on
the DASI [49].
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Table 3: Summary of current research on cardiac rehabilitation in breast cancer patients.

Author

Sample size (n)

Battaglini et al.
[41]

51 randomized
controlled trials

Bland et al. [42]

n � 68

De Jesus et al.
[39]

n � 24

DieliConwright
et al. [43]

n � 100

DieliConwright
et al. [44]

n � 200

Dolan et al. [45]

n � 152

Howden et al.
[46]

n � 28

Hsieh et al. [40]

n � 96

Juvet et al. [47]

n � 3418
25 randomized
controlled trials

Kirkham et al.
[48]

n � 73

Knobf et al.
[49]

n � 154

Lee et al. [50]

n � 4980

Methods

Results
Improvements in cardiorespiratory function, body
Meta-analysis of studies including aerobic
composition, strength, and patient reported
exercise, resistance programs, and combination
outcomes including fatigue, depression, and
of both.
quality of life.
Women with early stage breast cancer receiving
Higher baseline quality of life (QoL) predicted
chemotherapy participated in supervised aerobic
higher attendance during chemotherapy and
and resistance exercise was prescribed three
higher QoL, measured at the end of treatment, and
times per week during treatment, then one to
predicted higher attendance posttreatment.
two times per week for 20 additional weeks.
Adherence rate to exercise program was 30.3% to
Feasibility study looking at a 16 week CR
the cardiac rehab program. Improvements were
prescription program for breast cancer patients
seen in fatigue. No signiﬁcant changes in body
who rated their fatigue >4/10 after completion of
composition, aerobic exercise capacity, and
adjuvant chemotherapy.
activity patterns.
Randomized controlled trial with 16-week
Sarcopenic obesity, circulating biomarkers
combined aerobic and resistance exercise
(insulin, leptin, and adiponectin) signiﬁcantly
training in ethnically diverse sedentary,
improved postintervention at 3-month follow-up
overweight and obese survivors of breast cancer
At postintervention, the exercise group was
Breast cancer survivors with sedentary lifestyles superior to usual care for quality of life, fatigue,
who are obese or overweight participated in a
depression, estimated VO2 max , muscular
16-week aerobic and resistance exercise training. strength, osteocalcin, and bone speciﬁc alkaline
phosphatase.
Retrospectively analyzed eligible charts of
patients that participated in weekly supervised Cardiorespiratory ﬁtness (VO2 peak) improved by
personalized aerobic and resistance exercise 14% with signiﬁcant improvements in quality of
life and depression scores.
session for 22 group sessions plus 12 group
educational sessions
Patients with early stage breast cancer
undergoing anthracycline therapy chose exercise Exercise training attenuated the VO2 decrease
training or usual care. The exercise training during chemotherapy. Functional disability can be
group completed 2 × 60 minute supervised
prevented with exercise training.
exercise sessions per week.
Patients in individually supervised oncology
rehabilitation setting based on CR. 2-3 times/wk ↑ VO2 max and time on treadmill for all groups.
both aerobic and resistance and stretching.
An increase in physical functioning and a decrease
Systemic review of trials with physical exercise
in fatigue were observed after a physical exercise
intervention versus a control group.
intervention.
Chemotherapy resulted in increased HRrest and
tachycardia, decreased blood pressure.
Patients received adjuvant chemotherapy
Anthracyclines, trastuzumab, and left-sided
participated to varying degrees in supervised
radiation were associated with HRrest elevations
aerobic and resistance exercise during
and impairments of HRrecovery, but exercise
chemotherapy +/- radiation and for 20 weeks.
training at least twice a week mitigated these
changes.
Fitness center intervention had signiﬁcantly
improved time on treadmill, improved heart rate
Randomized controlled trial. Compared 2recovery at 1 min, greater MET minutes/week, a
month aerobic-resistance ﬁtness center
trend for improved insulin resistance, and stable
intervention to home-based physical activity.
insulin levels compared to the home-based
physical activity group.
Analysis and multivariable linear regressions
were used to examine the association between
resting heart rate and metabolic risk factors,
Strong positive association of resting heart rate
including systolic blood pressure, diastolic blood with fasting glucose, triglycerides, and diastolic
pressure, glucose, triglyceride, total cholesterol,
blood pressure in breast cancer survivors
high-density lipid cholesterol, and low-density
lipid cholesterol in breast cancer survivors.
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Table 3: Continued.

Author

Mutrie et al.
[51]

Sample size (n)

n � 203

Methods

Results
Functional and psychological beneﬁt after 12
weeks and six months later.
Patients in a 12-week supervised group exercise
No improvement in general scale of QoL (FACTprogram during treatment for early stage breast
G).
cancer, with six-month follow-up.
Improvement in mood and cancer speciﬁc QoL
scale (FACT-B).

There have been conﬂicting results on changes in cardiac
markers from a CR program. One study did not demonstrate
an improvement in heart rate and blood pressure from
baseline to postintervention [45], while another study
showed normalization of BP and lowering of HR with an
exercise program [48, 50]. A previous study observed a
signiﬁcant improvement in circulating biomarkers such as
insulin levels after exercise training in obese breast cancer
survivors [43]. The current study is the ﬁrst study to look at
changes in fasting glucose, cholesterol, and BMI during an
exercise program in breast cancer patients. There was a
decrease in cholesterol and glucose after completion of the
CR program, but the change was not signiﬁcant. However,
since the study was a feasibility study, it was not powered to
detect a diﬀerence between the values for these endpoints.
A CR platform is known to improve the quality of life for
patients that complete the program, including improvement
in fatigue [41, 47]. Several studies have also shown similar
beneﬁts in QoL in breast cancer patients undergoing exercise
training [44, 51]. Our study found that there is a signiﬁcant
improvement in BFI and QLQ-C30 over the intervention
period and at follow-up, supporting the previous evidence
that fatigue and QoL improve after a CR program [41, 47].
4.1. Strengths and Limitations. The strength of this study was
that it used an existing outpatient CR program, including its
convenience to hospital-based services and treatments,
which have been shown to be eﬃcient and cost eﬀective from
a health services perspective [42]. Most private insurance
carriers and medicare reimburse for CR utilized for cardiac
conditions but not for cancer survivors, given current lack of
evidence. However, unlike many exercise programs, CR is
characterized by its evidence-based protocol and attention to
exercise principles. The AHA released a statement in 2019
emphasizing the importance of CR in the cancer survivor
population [12]. Additional strengths of the study include
the broad eligibility criteria, which is more representative of
the general population of breast cancer survivors. Moreover,
the use of objective measures such as VO2 max, vital signs,
biometric studies (such as cholesterol and fasting glucose),
and the use of validated questionnaires strengthened the
study [21–23]. Furthermore, the study is one of a few
prospective CR intervention studies for breast cancer
survivors.
The limitations of the study include the follow-up at only
8 and 14 weeks from the last treatment. Further investigations with longer-term follow-up are needed to assess
duration of the positive eﬀects of the program and to further

evaluate changes in cardiac risk factors. Another limitation
of the study includes the overall general health of the participants and lack of signiﬁcant comorbidities in the CR
program. Unfortunately, many patients in the oncology
population have other comorbidities that would modify
their CR program prescription. Moreover, the satisfaction
results with the CR intervention are limited due missing data
from the people who did not complete the program. Additional important limitations of our study include the lack
of a placebo comparison arm, lack of blinding, and no
treatment randomization. Therefore, the next step is to
complete a double-blind, randomized controlled trial with
signiﬁcantly larger study population, comparing VO2 max
in patients undergoing CR program to current standard of
care follow-up, which does not include an organized exercise
program.

5. Conclusions
Taken together, our study suggests that CR program in
breast cancer survivors is feasible but does not meet is
predeﬁned criterion of feasibility. Adherence to the CR
program among breast cancer survivors was similar to the
general population. While a CR intervention in breast cancer
survivors showed a modest improvement in VO2 max and
CVD risk factors, it did demonstrate an improvement in
patient reported outcomes of increased physical activity,
fatigue, and QOL, in a signiﬁcantly limited period of time
suggesting that a larger randomized clinical trial would
enroll much higher patient number that should be
undertaken.
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